Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you. And good morning to our report for the second quarter. We start with me giving a company update, and then Svein Martin will provide a financial update. Looking at the highlights of the second quarter. Uh, two days ago, uh, we came out with revised targets. Uh, the performance is a bit behind plan, and I will get back to that. It will be the major part of my presentation. Um, but other updates, um, we now have our own functional ambient listening functionality built into three of our products. So that means that the AI is listening to the meeting between the patient and the doctor and automatically proposes a medical record. We have integrated this functionality into three products. That's Webdoc, WebdocX, and Metodika. It's only Webdoc that's selling it now, and we have roughly 30 users live at the moment. So it's going forward. We continue to develop functionality and I will get back also to this. What I think is the major highlight of the second quarter is that we sold the first primary care centers in Vgr since 2018. I mean, 2018. So it's in total eight clinics, which will give us an ARR of roughly 3 million SEK starting January 2026. And I think, I mean, it's always fun to sell to new customers. It's a pretty big customer. Um, or it's not new. They have Webdoc in other clinics already, but securing new contracts is always enjoyable. Uh, but I think what's the most important is the sign that our customers in VGR are less worried than they used to be about Millennium, and that they actually go ahead with the change of systems. Now, I think it's a very positive sign. And we have other positive discussions with primary care centers in Vgr. Um, but we're very happy for this contract with Medtanken. It will mean a bit of work this autumn to get them live, and then they will start becoming paying customers 1st of January next year. We have also announced new medium-term targets two days ago. I will also get back to them a bit later in my presentation. And finally, with the rapidly improving cash flow we have, and also since our acquisition pipeline is very targeted, we know exactly what we want to acquire. Uh, we don't have any other discussions. We have had a few discussions, and we'll take them at an orderly pace. Uh, we have too much cash on hand. Uh, so that means that we're now starting and initiating the buyback program of up to 150 million SEK until the next AGM. Profitability continues to improve, even if we are a bit behind the plan this quarter and the first half of this year. I will therefore go into the main reasons for the revised targets for this year. Um, if you're looking at these three: Ad Opus, Metodika, and our AI investments, starting with Ad Opus, we are so far this year, 3 million kroner behind plan. Um, we have had a long period of underperformance and churn in this business unit. It's our smallest business unit. Most of these 3 million kroner are behind plan. It should be said, is. That is taken into account for the restructuring of the organization. That means costs for letting people go are most of those 3 million. We didn't expect this year to be outstanding. Um, so we're doing a reorganization where Ad Opus and Accuracy are combined into one unit. Activities have done a great job with sales, providing excellent support and delivery to customers. And we think that Ad Opus can learn a lot from that. Also, they share a lot of software already. So it's more efficient to be in one organization. So it's a way of saving cash. Um, I strongly believe in Ad Opus still. Uh, the reason I do that, uh, even though they actually are shrinking by 25% in the second quarter, which is part of the reason for restructuring, is that we are launching the new system, Ad Opus web, uh, which is a completely newly built system replacing the old system. Uh, it has taken some time. Uh, but now we have. I've been interviewing a lot of customers within Ad Opus. And the largest one, Vertex, is now really, really happy with the product. And they're providing testimonials affirming the quality of the product. Uh, you can see them on LinkedIn and also on other social media. Uh, and I think Ad Opus web is a great product. Uh, we have to learn how to sell it. We have to learn how to implement it in a good way to make it easy for customers. But once we do, we will be able to really sell. But what these organizations do is position us within a cost structure that gives us the time to succeed with that as well. And that's the main reason. And what that means is that in the coming 12 months, we will not attempt to do any new sales of Ad Opus web. We just try to move all customers from the old Ad Opus to the new Ad Opus web. Then, when we have happy customers in that solution, we can start selling to new customers. And then we have all these present customers speaking positively about the new product. But it's very difficult to do both at the same time. So we have to take a step back, lower the pace a bit in that organization, lower costs so we can take time to move customers over to the new product and then sell to new customers. And I think it will be a really beneficial structure to be in the same structure as at Carasent. And that means then that the head of Ad Opus has had to leave the company and also another employee in that part of the organization. So it's for really big caregivers that use the same system across multiple clinics and hospitals. Uh, and those types of caregivers usually want some adaptation. So if you're looking at Webdoc, which is for single clinics or groups of clinics, we don't do any adaptations at all. Um, but in Metodika, a large caregiver like Volvat, which caters to all Swedish speakers, is based in Norway. Uh, they're implementing in all of their units. We are replacing roughly five different HR systems. Uh, then you want as a customer to be able to have some adaptations for your business. And that's what we're doing at the moment for Volvat. Um, I think we had a bit of mission creep. So they've been wanting a bit more functionality than we had planned for originally. Uh, such as the patient portal, which will drive profitability in the future. But it has increased the amount of work now, and it has taken more work than we planned to get everything ready for Volvat. Volvat. This has also meant that we have not had time to work with existing customers as we used to. So we have a significant backlog of change requests from customers, and that's a source from which we usually generate substantial revenue. So in total, we are 4 million behind the plan for the first half of the year. But looking from another perspective, our consultancy revenue is 4 million behind what it was two years ago. Even though we have more employees, everyone is focusing all their time on Volvat. And that will be 7 to 9 million of new revenue, just for the system and for different add-ons. But there's no consultancy work in those numbers. And then we should also have the other 4 million that we're now not getting for consultancy work for other customers. So it's quite a big swing of somewhere around 11 to 13 million that we should see due next year from that product alone. And this is a part of the cost when we move from selling licenses, doing consultancy work to actually selling subscriptions instead. And as most of you know, the majority of our products have always been subscription-based, but Metodika has not. The final major reason is AI investments. We have, so to speak, been playing around with technology. For quite some time. We have been looking at what other players do, and we became very convinced of the potential for AI to lessen the administrative burden of our customers, which is the big burden they really don't like to spend time on, and they spend a lot of time on administration. AI is really good at helping with that. We also believe strongly that building it into the systems is a great way of doing it, because then you can access all the information around the patient when you do it, not only listening to the conversation between the patient and the doctor. We can also use all the other information that is in the medical records and in the calendar and so on. So we can really do a lot to unburden our customers. I also think it's a technology that we shouldn't say no to. We should invest in that as well, because I think that's where a lot, potentially a lot of the future lies. So we decided at the beginning of the year to invest more into AI and to partially invest in new competencies within the organization. Uh, I'm not very stressed about it. I think there's great potential going forward. And we have no need to be first. We have the HR position. That's the difficult one. You don't leave that easily as a customer. You tend to stay there. So as long as we can, we remain competitive. It's easy for our customers to move from another competing solution to our solution. That being said, I think that we're also selling competitive solutions for this type of support. And we'll continue to sell, as our competitors or partners tend to put it that way. Solutions. And I think for some customers, one solution would be right. And for other customers, another solution would be the right. Uh, but I think for very many of our customers, our solution will be the most appropriate. It will be completely built-in, with no need to work in other systems. And I will have access to much more information than in an external system. Um, today we have ambient listening. So, we are listening to discussions between the patient and the doctor. And next, we will start filling out different types of forms, referrals, sick notes, and so on to really unburden our customers, but we still have quite a lot of work. Um, just for example, this week we're releasing new functionality, which will cut the time it takes to propose a medical record by roughly a third, I think. So quite a big improvement for customers that are already live, uh, coming this week. But these three areas are the main reasons for the revised targets. Um, I think that if you look at Volvat, it's really something positive for us going forward. It's, of course, negative that we're incurring higher costs on it than we planned, and it also prevents us from generating other types of revenue this year. But it will pass. Um, a big part of Ad Opus involves restructuring costs for transitioning into a leaner organization, which will help us going forward. And I think it will be really good going forward. And I think it was worth investing a bit more than planned originally. So those are the main reasons for the revised targets, which now look like this. So you see, the revenue has been slightly lowered, uh, and the EBITDA, as well as the EBITDA minus CapEx, is a bit lower by roughly 10 million kronor. Looking into our new medium-term targets, we have great products, and I'm really proud of the products we have. What I think is even stronger is that we invest quite a lot in our products to increase the distance between us and competitors. So we say that we invest more than most of our competitors. Um, and that means it would really help drive growth going forward. And it should, uh, and will really allow us to grow with an average of 15% over the coming three years, together with good cost discipline. And this will allow us to continue to rapidly improve profitability, reaching an EBITDA margin of 35% with CapEx of less than 10%. So these are our new medium-term targets, which we believe strongly in. And I think also it's wise to guide on this, uh, horizon when we are in this type of rapid transition from where we used to be. With those words. I will hand over to Svein Martin Bjørnstad.
Uh, but I think for many of our customers, our solution will be the most appropriate; it will be completely integrated with no need to work in other systems. Uh, starting off by looking at the financial highlights. Uh, as discussed, we are a bit behind the plan in Q2. Um, uh, but, uh, in general, I would say the underlying financials continue to develop in the right direction. Our IRR grew by 27% to 317 million, including the backlog of signed, not yet implemented contracts. Uh, the reported recurring revenues grew 13% organically in the quarter with a net retention rate of 109%. And as we have talked a lot about during the last year, the pace going into Q2 was not that strong given the churn we had. We have seen customers using Webdoc go bankrupt. So, uh, most of that, as we spoke about last quarter, took effect at the end of Q1. So this affected the pace going into Q2. Um, the positive is that the pace going out of Q2 is stronger, which I will get back to. On the profitability side, our EBITDA margin was 15% and EBITDA minus CapEx was 3%. So there are improvements compared to last year, but we are still a bit behind our targets. This slide shows a key metric for us. Uh, that is how we are able to convert our revenues into profits. Um, and here we exclude the acquisition we did last year, Data-AL. And excluding that, the revenue growth was around 8 million. And then COGS naturally increased by around a million. Uh, you see that the operating expense decreased by 4 million compared to last year. But part of this is that last year was high, driven by a one-off cost of 2.5. And then we see that the big increase here on the cost side is the personnel expense. Uh, it should be looked at in connection with the CapEx decrease. So because, uh, that's like the total cash cost for our employee base, those two combined. And that increased by around 6 million. The reason for this is mainly the biggest part of that increase is the restructuring cost that we had in Norway and also the option program we executed in Q2. Uh, in total, these costs amounted to close to 4 million. So adjusted for this, the increase is not that significant on the personnel expense side, but looking at the overall effect, we converted 56% of the revenues into EBITDA. Um, and if we had adjusted for the one-offs last year and the special costs we had in the quarter, then we would have been close to our target, but still a bit behind. Uh, our internal target for this is converting around 80%. We have taken more steps on the cost side this quarter, removing a few more roles in addition to the Ad Opus employees that we didn't see the need for, and this will help us in H2. Uh, and we need to be around our target there of 80% conversion to reach the 2025 goals. The new goals. Uh, looking at the figures, we grew from 252 million to 317 million. On the organic side, we grew by 36 million in upsell, or 16%. Churn was 9 million, and new customer growth was 12 million. And the reason the two main factors driving the growth were that we onboarded several new large customers and clinics in Norway for queries in addition to a strong upsell for that product as well in the quarter. So we added around 7 million towards the end of this quarter for queries alone, which is really strong for that product. Partly, it involves this contract we have talked about. Um, and the second effect is that we adjusted the prices for several smaller Webdoc customers that were not paying enough compared to their production. So that added a couple of million in ARR as well. On the churn side, it's a bit higher than normal due to reasons we have discussed, including the churn in Webdoc related to the bankruptcies, as well as a high churn in Ad Opus, which we have talked about before. But in total, the net effect is that we end the quarter at an ARR growth organically of 17%, which is decent compared to what we reported in the quarter. Looking at the P&L. I talked about most of this already, but we landed at $83 million in revenues, up 26%. Gross profit margin remained stable at 85%. Then the significant rise in costs is attributed to personnel expenses. Despite that, EBITDA increased from 8 to 12 million within the quarter and the EBITDA CapEx improved from -1 to 2 on an adjusted basis. Um, and so far this year, we have improved from minus six, um, in EBITDA to plus seven. So a good improvement. But um, still a bit behind what we had expected. On the cash flow side, we are of course helped by these improvements in profitability, lower CapEx as well. Um, if you look at the cash flow in the quarter, it was in total positive by a couple of million for the first half of the year. I've talked about this in the past few quarters, but we had these really strong expenses as the costs were allocated in Q4, but the invoices were paid in Q1. So that affects the working capital for this year. Also, we experienced some currency effects when we exchanged the cash from NOK to SEK in Q1. So, normally our working capital helps us and supports the cash flow. Uh, but this year it will be, um, a bit affected by these relisting expenses. Um, so that was what we were going through. And then we can open up for Q&A.
If you wish to ask a question, please dial the Pound key. Five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Elvin Roger from Denaby Carnegie. Please go ahead.
Hello, Daniel and Martin. I hope you are well. And good morning, thank you for keeping us busy throughout this week. I have a couple of questions from my end, maybe beginning a little bit with the restructuring of Ad Opus and the merger with Altiris. Are you, when you look at the current organizational setup of the group, happy with what you have now, given these changes you have made, or do you see any obvious further improvements down the line that you're looking at? And, uh, how many people roughly in total did you have to let go from these initiatives in the quarter?
Yeah. Thank you. Alvin. Uh, so regarding the restructuring of Ad Opus in general, we're running quite a decentralized organization because we think it is most important to be close to our customers. That's for a number of reasons. The first one is to develop solutions that actually fit our customers. The second is that sales and support should truly understand their customers. So in many parts, it's a decentralized organization. Um, but in some areas we really have some clear synergies, and looking at Ad Opus and Altres, they share the same software. So, there are more and more people working on the same platform, and it makes sense to be the same organization. Uh, also, IKEA is doing a great job with sales and delivery. Um, they've had a really, really good quarter. And as Marty mentioned in his part, we ended the quarter really strongly with new customers going online. And that's largely thanks to the organization doing a great job. The other organization, uh, I think can learn a lot from, uh, and we gain from being part of that organization in that sense. And it also allows us to save costs. Uh, but in general, I think the decentralized structure is quite good. Uh, we will always review the organization and do what we believe is best at each point in time for the long term. Um, and, uh, it might be that especially with the acquisitions we're looking at, they might fit well together with something we already have and therefore will be combined with the present business unit. For example, in Ad Opus, there were only two people let go. It was the head of IT and another person. It's our smallest business unit. So it's quite a small organization, but it's always a bit more expensive to let the head or CEO of a company go. Um, also, we have had other roles, um, that were let go in the entire group, uh, in the quarter to also lower costs. But the numbers that are in those 3 million, it's only those two, together with how much Ad Opus is behind so far this year? Did that answer your question?
Yes. Yes. More than enough. Thank you. Uh, and then, uh, maybe looking a bit on Medtanken, finding a customer here in Västergötland is very positive to see. Of course, it's notable that the customers are making decisive moves. Was there anything specific that made Medtanken go ahead right now? I mean, it's been pretty much of a stalemate in the region so far, but have there been any changes that made them go ahead right now? And you mentioned that you have several good discussions with other clients there. Do you see a similar kind of development as you've had with Medtanken with those customers? If you could comment a little bit more on that.
Yeah. So Medtanken is quite a big caregiver. Um, I think I'm told that they have a turnover of a bit over 1 billion SEK, and they have a lot of primary care centers in, um, in Jutland. So for historical reasons, they've had Webdoc in roughly half of their clinics. And, a CDM software in the other half of their clinics. And I think that they've seen that, over time, the difference between those two systems has increased. So since 2018 until now, there has been quite a significant improvement in Webdoc in terms of functionality and what we offer. And I think they've seen that there is now quite a significant difference. So I think that's why they pulled the trigger, so to speak, and changed. So, um, they will not be in new sales in our columns. They will be in, in growth in existing customers. Unfortunately, they say when we look at the numbers in Q1 next year. But, um, so I think the reason is that they see both software systems and they see the difference. I think that's quite a significant reason. And the other one is that everything coming from VR, it seems very unlikely that any system will be pushed out anytime soon. And I think that all of the caregivers see that and have discussions with other primary care centers. Uh, we have no present discussions with a primary caregiver of the size of Medtanken switching all clinics. So it will be more one clinic at a time in that case. But I think it's a really positive effect and positive signal, to run and we'll try to create some media around it after the summer to try to influence the politicians locally in Arendal.
Okay. Great. Thank you so much. Uh, and then, regarding the ambient listening and the AI tools, I just want to clarify, when we were talking about AP users, I mean, you can equate that to, I guess, 80 physicians. So it can be several in the same clinic. I guess, could you clarify on that and roughly estimate how much is the revenue per user, if you can give some insight on that? And then finally, on the 30 users you have live now, have these been using the other tools that you have partnered with, or are these completely new to this kind of tool?
Yeah, yeah. Um, so it's 30 users that are live. Uh, I've. Yeah. If I was unclear, it's not only 30 users, and those are individuals. Yeah. So that's correct. Um, and at this stage, we started focusing really on this product at the beginning of this year. So it's been about half a year since we started investing in it, but we're not investing very heavily in it. So I think we still have some work to do to catch up to competitors when it comes to the quality of all parts of it. Then we have advantages fully built in and so on, but we're rapidly catching up. Uh, so I think, for example, this week we will cut. The time it takes to wait is being reduced. It will become a third of what it was last week, and then we will probably be the fastest in the market. I believe delivering the actual result of the discussion with the patient is extremely important for the physician. Um, so these are the kinds of improvements that we need to do. Um, but we'll do them. And I think we have a clear roadmap on how to improve and how to move forward and add more functionality. Uh, but as I said before, I'm not stressed. We don't need to be first. I think it's quite good from our position to look a bit at what works for our customers and what doesn't work. And then we build the things that work because there have been so many investments in health tech that have not been picked up by the customers, even if they've been good initiatives. However, what we have observed is that this really suits the users. Many users like it, so that's why we started investing in it. Um. Um, the way they pay is that today we charge 750 kronor per user. Uh, so we're cheaper than the competition. We still have really good margins on that. The reason we can be cost-effective is that we're not using American cloud services, which I believe have their own advantages, but we're operating in our own server environment. And that means that, uh, we have quite high fixed costs for the AI solutions and the costs we are already incurring for it in terms of server capacity and GPUs. We can scale to at least 500 users without a problem. Uh, so, uh, probably quite far beyond that, most of the costs. So, uh, there are some costs, but, um, so that's where we are at the moment. We are in the early phases, we have received positive feedback, we have some improvements we need to implement, and we will start acquiring users. The ones that are lying now have. Many of them have tested the different solutions that are out there. So, it's still early adopters that are using this type of technology, I would say. And it's still a minority, a clear minority of all users in our system that use any such solutions. Uh, but I think going forward, uh, it's likely that we'll see more and more uses of this technology as it gets better and better and also as it spreads. And healthcare is really conservative. It's slow in moving into new technology, but many are big fans and they really like it. Uh, so over time, I think it will really be a major point. But it's in our plans. It's still a cost throughout the entire year. It's not something that drives a lot of profitability this or next year. Did that answer your question?
Yes. Very clear.
Just yeah.
Yeah, yeah. Your answers are very good. Just one clarification. 750 crowns per user per month, I guess, or.
Yes, per month. Per month. Thank you, sir. So, it's part of our strategic plan.
Yeah, it is.
You can say it depends on how much you use Webdoc, but it's a little bit less than what most pay for the entire Webdoc. If you compare the amount of time spent building this to the time spent on Webdoc, it has really good revenue per hour invested.
Mm. Good. Uh, and then, uh, maybe a little bit on. You answered a lot of my questions during the call, but I have a couple of questions about the financial targets here because you lowered the EBITDA target somewhat. Uh, but, I mean, looking at the H2 level. It doesn't seem like there's a significant difference compared to how it was before. It's mostly been due to what has occurred in the first half of 2025. How confident are you in the current 2025 targets? I guess you have a better line of sight now than when you set out the initial target more than a year ago? And is there some uncertainty still regarding the 2025 target, given the implementation of Volvat that can maybe delay or affect that? Or how should we think about that?
Yeah, yeah, compared to our own plan, we still have some effects in the second half too. So, um, but as I've said for quite some time, we felt that there was very little space left in the targets. I think I said it already at the end of last year that I was a bit worried about the targets, and now, of course, we have much better visibility. It's not, the targets are not, uh, it's not a walk in the park to get there, so to speak. Uh, we still have to succeed in what we're doing. Uh, it's, uh, so to speak, our best guess of where we'll end up. And I think, uh, we're on a good track to get there. Uh, we're taking a lot of measures in the first half that will help us in the second half. Um, we'll always aim to deliver a strong Q3. We have the vacation effects there. So I think, uh, the autumn, I mean, obviously, if you look at the numbers, the autumn has to be really good. I expect autumn to be really good, as you say. There is, of course, some risk with Volvat. We're moving from six different systems into one. So, I mean, Millennium and Nvidia didn't import any data from any old systems. So, and that's quite a complex process because you have the same patients in many of those systems, and each system saves data in different structures; meanwhile, they continue to meet patients all the time. Only 500 employees in that organization. So, it's not the easiest process in the world. We've done it before in Metodika. We know how to do it. We moved entirely alias Norway into Metodika a couple of years ago. So I think we have great experience in doing it. Obviously, we underestimated the amount of adoption work needed. Uh, it also took longer to get access to our competitors' databases that we need in order to export the data. But we have that now. Um, so there is a bit of risk in Volvat, I would say, but we expect to manage and reach these targets. It's not a walk in the park, but we should be able to hit that.
I expect autumn to be really good, as you say. Thank you. And, um, finally, I should let some other people ask a question as well. But I have one more. Uh, it's a bit on the new medium-term targets. You said an average of 15% organic growth between 2026 and 2028. I'm just wondering, because that feels kind of like the organic growth that the business grows on a normalized basis, given your higher net retention and the normalized low churn and so on. But how much of that figure do you factor in from the organic growth optionality provided by the opening in Stockholm, the expansion in Germany, the AI tool, and perhaps even the surgical module? How should we consider and how do you think, uh, when incorporating those four factors into this target? If you can comment a little bit on that.
Yeah. And that's, I mean, obviously difficult looking that far into the future. Uh, so I think that, I mean, I think we really have great opportunities. If you look at Stockholm, you look at AI, you look at Germany, I think we have really great opportunities. On the other hand, things always happen, as we see in this quarter. And I think this audience understands that things happen, and it's dangerous to put out previous targets based solely on perceived opportunities. I mean, yeah, being in my position, I obviously believe very strongly in everything we do. So, um, I could see us growing much faster also. Um, but I think the sensible approach is to set targets that you feel very comfortable about, and these are financial targets. Then you have other targets, and I mean, we're trying to drive the business faster than that. Uh, and then you have internal targets on what you want to accomplish, what you want to do. Uh, but I think when you go about financial targets, you need to be a bit prudent. And I think those targets are a bit prudent, especially given what we have just done two days ago—the first profit warning I think I have ever given as a listed company. So, I'm not too happy about it. So I think it makes sense to set targets, which, I mean, also, this is not a walk in the park, but the opportunities are much larger than that. So you have to find a sensible level to communicate and make sure that the expectations out there are reasonable. So that's, I think, what we try to do. It's not our business plan that we're giving out as financial targets, so to speak.
Fully understand? On the other hand, things always happen, as we see in this quarter. That is very clear. Thank you so much for taking all my questions. I'll get back in line and see if there are any other panelists.
The next question comes from Frederik Nielsen from Redeye. Please go ahead.
Thank you. Good morning, Daniel and Svein Martin. I want to start with the primary care deal in Västergötland. I mean, is this really the start of perhaps the positive case that you talked about last year, discussing the potential churn and so on, starting to play out, or is that reading too much into a first new customer?
Yeah, I think it's reading a bit too much into it. I think it shows that customers are not that nervous about being forced into something very soon, but we have not yet gotten to a stage where they see it as risk-free, and that's where we would obviously like to end up. We're pushing different ways of getting there. The core process is still ongoing. I think there are a lot of other good reasons why it will be free. Uh, we know that some political parties are now pushing that also. Um, and the caregivers, of course, are pushing it quite hard. Um, on the other hand, the region doesn't want to give the private caregivers a lot of advantage over their own business. So that's the difficult part. Um, I think that sense will prevail, but, um, it's not guaranteed, and we're not there yet. I think what you should read into it is that our customers are less worried than before. They are, and we are now quite a lot better than the competition. And that's why they change, despite it still being a bit of a risk. Because you really don't want to change the AI systems unless you have to, or unless you really have to. But unless there are really good reasons to do it. So I think they obviously see those reasons. And that's really positive. So I would see it more as Webdoc doing a good job, and that the political risk is a bit less in the region. Um, but we're not there yet in the really positive case now.
Okay, great. And could you elaborate a bit on the mix between the old and new product in Ad Opus, so we could get some kind of understanding when the negative trend might turn?
Yeah. So, um, Ad Opus Web, um, I mean, it's a completely new product. It's really forward-thinking. You have, they don't have patients, but I use that word anyway. Now, to make it clear what I'm talking about. They have the caregiver and the patient working in the exact same system. I mean, all of our systems have different types of patient portals, both our own and third-party solutions, where you can interact between the clinician and the patient, the clinic and the patient, and the hospital and the patient, and so on. Uh, but here they actually work in the same system. And I think that's really groundbreaking. I've never seen that before. Also, the UX is really well thought out, and it has a lot of automation that really helps the caregivers. The challenge is that it's a bit too new, so they move from older Ad Opus. And then they are much more efficient than before. So that's great. But not all customers want to embark on that journey. And I think that every time we develop solutions, they should always allow for you to work in your old ways. They should allow for new ways of working, but also old ways, because customers don't always want to change how they work and they don't want to change just because we tell them to change. And that's something we'll work on with the system to make it allow for the old workflows to be functional. It will be less efficient to work that way, but many customers will want to work in their old ways. So that's something we're doing. It's not really development. It's more, um, setting up the system. So that's something we can do fairly quickly. Uh, we have roughly three customers, one of them being the largest, who are fully into the new solution. And then we have many others who have started testing it. Uh, but that's also something I want to lower the pace on. I want us to take on like maybe three or four customers at a time, no more, to make sure that we do it really well. We take care of them and they are happy with the process. If we try to take too many at the same time into the new system, and it's, you know, everything looks different. Uh, and if we're not close enough to them, then we will have churn, even if the new system is good. They would appreciate it if they received the right education and support, with us really helping them every step of the way. That's what we need to do. That's what we do. Great in Webdoc and Volvat and many of our other products, and we've been trying to push it a bit too quickly, actually, in Ad Opus, I would say. Uh, I interviewed some of the ones that left us. And to me, it's quite clear that the problem is we tried to move them over a bit too early, but also that we haven't yet learned how to move customers into the new system. So I think we're getting there, and it's really good to see the first customers being happy. It's just in the last two months that they've been prepared to actually be, um, what's the English word—they are out there talking positively about the system and ready to recommend it to other users. So we just about got there. Um, and in the coming 12 months, we will not see any growth in the system. I hope we don't see any more churn. There will be some churn that's not yet in the numbers. So, uh, what really made us reorganize now was that we lost the second-largest customer. Uh, so, uh, that will mean a return in Q1 next year. Uh, not a huge amount of churn. I mean, still, Ad Opus is our smallest business area, so we shouldn't put too much time into that or it shouldn't guide us too much. But I think that it has the potential to really grow. And if you're looking at Ad Opus, since I think it was acquired back in 2018, it was initially in Amassoma before becoming part of Carasent a bit later. Uh, they've gone from 90 customers to 30 customers. Um, and that's because they've been building — uh, we've been building a new solution to replace the old one. And, uh, that has taken time. Uh, but now it's there, and I think we'll start winning back those customers going forward. And, and we have a much better solution than anything else out there. I think maybe it was the wrong choice many years ago to build a completely new system to replace the old one. I think you could have done it more gradually. Uh, but that's in the past. Uh, there were many right decisions taken, too. Uh, and, uh, that's why I think we have this kind of a new curve where we've been losing customers because the old one has not received enough attention, and the new one has not been ready. But now we're getting there. And the churn we actually had now was leaving for another old system that's actually very similar to the one we're replacing, just because they didn't feel comfortable enough transitioning to our new system. Um, because we were not close enough for them and we tried to move them a bit too early, we needed to lower the pace. I'm sure we will get the people there. Um, and the entire organization is robust. I feel a lot of energy. I think they like being part of this. It's a positive vibe. Uh, the development we do is done in Moldova, so. So, we have a low cost in what we're building. And it's groundbreaking in many ways. I think it's actually a groundbreaking system in many ways. So I look forward to that. It will take some time.
And if you're looking at Ad Opus, since I think it was acquired back in 2018, I think it was in Amassoma and then it went into Carasent a bit later. Thanks. That's clear. And so regarding ambient listening products in general, there seems to be mixed feedback. Reading some news articles about larger caregivers implementing those. So could you give us an update on the customer feedback regarding medicine?
Okay. Is that the report in GP about the implementation that you're referring to?
Yeah, that's one of the examples. Yeah. Yeah.
So, so I think it's important to note that the implementation of what they call AI, and which has been criticized in the media by doctors, is not AI as we see it. It's all speech-to-text. It's a Dragon. They call it. They call it. I don't know why it's a dragon. Nuance's product Dragon, which is an old speech-to-text solution that we've been selling to our customers for at least five years. Uh, many of our customers use it. It is a good speech-to-text solution, but it's just a speech-to-text solution. And that's what a leader is trying to implement. Uh, the reason I think they get this mixed feedback is that they also completely take away the medical scribes, the people. So the doctors do not get any support anymore with, you know, writing letters. So they move them into a completely separate building. And I think the actual reason why the doctors are upset about the new tool is due to changes in their workflow, not necessarily the tool itself. And I don't think it's the tool because that tool they are selling, we have sold to our customers for at least five years. I don't know exactly when that started, and we have many happy users of that product. What is going live now is what we're replacing with our AI solutions. So the ones that have been criticized are not ambient listening as far as I've seen in a year or so.
Great. That's clear. Um, and also regarding medicine, according to your website, you will shortly launch medicine broadly. Could you give us some flavor on that? I mean, what time period are we talking about? Approximately?
Yeah. So, um, we are selling it now. We're selling it. We have a process where we send out information about it to all our customers. Then I just talked about Webdoc. The other ones have not done it yet. And what we want to reach is those early adopters that are interested in being part of the journey, so to speak, who like the technology and are open to giving feedback. They are open to that. Everything might not be working perfectly yet, so they are happy to just be part of that process. And many doctors, nurses, physiotherapists, and others. They like to be part of development. They are close to our development people and get to be part of the discussion. They get to influence what we build. So what we have achieved is letting everyone know that it's coming soon so they're aware and don't commit to other products long term. Um, and then we've said that if you are interested in being an early user, let us know. And then we have a list of, I don't remember how many, that have contacted us saying that they're interested. So out of those, we have taken 30 live and we'll continue to take users live. Um, some of them are paying, and some are not paying yet because we moved from just offering it for free to pilots to now charging users. They will become paying users, and eventually, all will be involved. We have no hurry to make them start paying. The most important thing is to make them really happy with the solution, and then they will be happy to pay us. So that's where we're at.
Great. That's all for me. Thank you very much.
There are no more questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.
Yeah. Um, so we have gotten quite a lot of questions in the chat, so we'll try to be quick in addressing them. The first ones are from Nicholas. It's in Swedish, so I'll try to translate here. But the development for Volvat has taken more time than expected. Are you getting paid just for the development? Are you aiming for improvement? Are we expected to continue funding development going forward? Or. And do you see the risk of delays further into 2026?
Yeah. Historically, Metodika has typically been selling licenses rather than renting them and then charging for development. We're changing that around to renting it, then focusing on ARR instead and long-term value creation. Uh, so that meant in the Volvat deal that we halved the cost per hour for all adaptations compared to what we usually charge. Uh, we are still around break-even per hour, but we're not making any profit on the adoptions for them. Um, but also, I mean, we are the ones with the best view of how many hours it should take. So not all of it, but quite a lot of it. When it requires more work than anticipated, we have to bear the cost. It depends a bit, but in general, in most cases we are taking the cost, so that means we're actually losing money on those options. Um, but as I mentioned earlier, we have a really big swing next year. Um, it's a really complex big project. Uh, I think we're on a good track to deliver it to most of the users in November, which is the time that's set up there. We have some small systems that will move over in the beginning of next year. Um, I think we're on the right track to get there. Um, and, um, but it's not without risks, but it's our best guess at the moment.
Um, next one, when do you expect Germany to be a substantial growth driver? So, um, as we have talked about before, we aim to start having paying users within Webdoc this year, and then it will, of course, be a gradual step up in terms of growth. So the growth rates percentage-wise will be higher than the rest of the group, but it will not contribute significantly to the group's organic growth in the next couple of years. Um, but, uh, towards the end of the new target period, we could see that Webdoc is materially contributing, basically. Next one is regarding the AI solution. I think we have addressed that. Uh, uh, the question is, um, how much of your current user base is within the sweet spot for, um, medicine?
Oh, um. I think basically, as I see it over time. Um, all users that do a lot of documentation are in the sweet spot. Um, in the beginning it's mostly doctors; all doctors. Uh, but I think it will add to more and more users. I mean, as I see it, we will. For example, if you want to do a referral, you might not have to say anything at all. And you might not need to have the recording from the patient listed. You can just push a button, and we take data from different parts of the system to write a proposal. Uh, so I think that, uh, it will become, I think I said before, roughly half of all our users, um, who do notes to any larger extent. So I think that's where the future for users will be, but it will take time. Their healthcare is really slow at this, but this has been one of those that's been growing the fastest, I would say, of new technologies. So it's a real-time saver, and that's what everyone is looking for.
The next question is, can you sell it as a standalone product and how do you approach that?
Yeah. Um. Maybe, uh, we do not have an interface to, um, I mean, it's completely built into the different systems, and I think that's the advantage we have. And also we have access to a lot of data in our systems, but we aim to make it standalone for many of our systems. So potentially, uh, we could sell it to our providers, um, that are not part of our organization. Um, but that's not something we've taken a decision on and not something we have in our plans. plans, but that's something we have thought a bit about.
Next couple of questions from Richard. Um, do you do any NPS with customers, and if so, have you considered publishing them?
Uh, we don't have it today in a format that's consistent across our products. In general, I think that each product we have should focus on getting the feedback in the structure that fits them and not what fits us centrally or fits external parties. But I still think it's worth thinking about. But, um, we don't yet have a unified structure for all products. And also something I would like to have implemented. Actually, something I would like in all our systems is that it asks for feedback every month. Get the question kind of how was your experience with the system last month? Because then we could have much more real-time data on how they like our systems and how they experience them. If you have a period with some issues with the system, understanding how users really experience it would be valuable, but we're not there yet. Uh, we have not been able to prioritize that development yet, so, uh, I think we'll get there, but it's not a question for us.
Right? Next one, excluding Ad Opus, what do your churn levels look like? Are you happy with the levels? Um, yeah. So, Ad Opus accounts for close to 1% of the churn. So it would be approximately around 3%. Um, it's higher than what we have had in the last few years. And, um, I think most of it is related to these bankruptcies and, basically, churn that it's difficult for us to impact, basically involuntary churn. Uh, if we look at the voluntary churn, the customer is leaving us because they change the system, it's still very, very low, um, below 1%. So, that level is good. But of course, the involuntary churn hurts us this year.
And we don't really have a good explanation for why we had a lot of that. Now, to be honest, it's a bit surprising. Uh, I've been working in the private healthcare sector for a long time, and I haven't seen this many bankruptcies. And there's nothing really in the market that I see that would drive it. I think part of it is that some of the tech startups are not getting funding anymore. So that's a part of the churn that we can identify. But there's even more than that. And, uh, I think it might also be a bit that it just happened to be a couple of them at the same time.
Uh, we have not been able to prioritize that development yet, so, uh, I think we'll get there, but it's not a question for us. The next one relates to primary care, and I think we covered it quite well. But there's one question regarding the interest from primary care centers. Uh, will they need two systems, Millennium or yours, or do they simply not believe in the rollout of Millennium at all?
So I would say that if you change systems now to Webdoc, as discussed, I don't want to put too many words in their mouth, so to speak. But it is. I would say it's because you believe that it will not roll out and that there's nothing else being forced on them. Uh, at least for five or six years, I would say otherwise. You don't make that change. Um, it's not that you're planning for it being better when you have two systems that you might have to have for a few of them, but you wouldn't change systems for that scenario.
Great. Next one from Erasmus. Um, it would be interesting to know how you build up the 15% average growth, given the current growth rate in the low teens. Do you expect that to decrease as AI and Webdoc drive the growth, or what are the different growth drivers you see? Uh, so, as I mentioned, I think Webdoc will build up gradually. So it will be a very small part of the group during this forecast period. So basically, we see that the 15% is mainly driven by the current business we have. And tools such as AI will naturally drive net retention. But in general, the core business involves selling to new customers and offering all types of functionality, including AI. Will be the main growth driver as we see it.
Yeah, and we have improved sales quite a lot. Uh, we're selling more and more. We have this high churn, but we're also selling much more. Each salesperson is selling more. And actually, we're selling on an above plan. So far this year. So new sales are quite good and sales to existing customers are quite good. I think we can get better at both. But this is more of a top-down approach than a bottom-up one because, with bottom-up, you can end up in unpredictable situations.
Yeah. And I would say that Webdoc will be a very important driver of growth, which will probably grow above this target. And then the rest of the business is expected to grow at a slightly lower rate. Can you provide an update on the operations? The surgery module?
Uh, yeah. Uh, so, um, we have, I think it's now two pilots running. We have two new clinics, quite large clinics starting after the summer, which are still existing customers. I think this, and they are all paying customers. They will not pay from day one, but they will be paying quite quickly and at a quite good level. Um, and, um, we will now start really targeting the surgery clinics, uh, that are not well-documented today. It takes time to convince a clinic of 50 to 100 users to change software, from the point that they start thinking about it after a meeting and we're showing them things. I think it generally takes probably a year before they actually commit to changing. Um, it's a very slow process. We're doing the best we can to really push it. We have really good feedback from the users of the system. We still have some functionality to add to make it even better. Um, but I think it will be over. This period will be a really important part of the growth for a clinic, especially in Stockholm, if you have insurance patients, which many of them have, and it is in all of their strategic goals to improve on that. And if you have surgery, then Webdoc is clearly a better choice than what's out there for you. Uh, more than other cases, even more than other cases. And if you also want to have different types of online tools connected directly into the system, then it's really clear that it's the best by far, I would say. So that's really the sweet spot to grow. But it's also when we talk about big customers and quite long processes.
It would be interesting to hear your thoughts about Scorm. It would be interesting to hear your thoughts about Scorm. Now that the smoke from VR's launch of Millennium has settled down somewhat.
Yeah. So, um, they are saying that they will implement Millennium still, I think. And I always viewed it as having a much better project around Millennium. And they have a better version of it too, I would say. And what we went live with, involving an extremely large number of users, was something that was not even tested in a pilot. And to me, I think that's really strange. We would never, ever do something like that. Um, Scorm has taken a much more sensible approach. And they had test versions and demo versions up and running way before the launch, and they still haven't gone live with any, not even a clinic, I think. So, they're much better. But what Scorn has done is that they're saying now that Millennium will replace far fewer systems than they planned from the beginning, and I think that's quite a good process for us. And there might be and there seem to be openings where Webdoc could be used for certain parts of care in Stockholm that we had not planned for. And it's actually not still in our plans, but there seems to be some openings that are positive. Uh, I cannot say more about it yet. Um, and I think that it's not bad for us if Millennium eventually goes live in VR, as it doesn't have to be just for the hospitals. They don't have that much to choose from. Why not collaborate with Millennium? There's nothing significantly compelling for them in choosing us. And then let the primary care use Webdoc. I think that's a sensible choice. Or let the primary care choose between all the systems that are available for primary care. So, um, but we'll see if we get to that point. That's not what's in our plans, not in our targets, but it's something we're working towards next.
A couple of questions for you. Um, could you comment on the development in Stockholm? Do you see clients shifting away from CGM already or not yet? And secondly, have you seen private clinics complaining about CGM software given their decision not to invest further? Uh, do you hear more about bugs, etc.?
Yeah. Uh, to answer the second question. First, uh, yeah, we heard from customers that they don't really understand how that software is going to last until the end of the decade, as it's in the plans. Um, so yeah, there's not much happening there, and that's understandable. We had a system that we knew was going to be closed down in five years. I think we would invest very little in it. So, uh, it makes sense. Um, and, uh, the difference between that system and ours will increase even more over time. Um, yeah. Uh, quite a lot of our new sales are in Stockholm. Um, it's a clear focus for us. Um, and, um, we're working hard to make sure that everyone knows about us. Um, and I think for every new customer we get in Stockholm, more and more get to know about the system, and more and more talk about it. And it helps us in the new sales.
Uh, next one. How is the development in Germany? Could you comment on that?
Yes. Uh, I think the Data-AL business is running really well since the acquisition. Uh, actually, it's a bit better than we had planned for. Uh, we're winning customers. We have quite good results in the business. Um, uh, we have now combined the R&D departments of the three products we have on the German market into one organization so that we can have clear prioritization. I mean, obviously, we have to maintain the software we have there already on the market. We have to do some development for the Data-AL software that's going to live for quite many years still, for some of the users. Um, but we focus mostly on, of course, on Webdoc. Um, whereas before, uh, we have the aim to get paying customers now during the second half of the year, uh, it will not be a big part of the revenues or the growth in the autumn, but it's nevertheless extremely important to start getting paying customers and start getting customers that can talk to other customers about our products.
And the next question is from Christopher. Uh, in regards to the profit warning, when did you realize an update before Q2 was necessary? And what is the main learning from this process for the management?
Um, so it's difficult to say an exact point in time when you realize. There should be a buffer in our financial planning. There should always be a bit of a positive difference. Um, I think the main learning is, um, I think our medium targets are a bit more. They have more space in them. I think that's an important part. There is more space for things not going as planned. Um, so I think that's probably the main learning to ensure we have that type of space. Um, from, from our perspective, there are so many opportunities, so much good we can do, um, so much value we can add for our customers that it's, uh, it's very easy to see all those opportunities. And I think that having some space in the targets and what you actually see as achievable is an important lesson.
The target for CapEx is lowered significantly from 44.9 to 35 million. Could you elaborate a bit more about this? I think, yeah, we had talked a lot about it in the call, but the main reason here is that the result in H1 is a bit behind what we expected, and that is partly driven by this extra cost. We have talked about but also this development for Metodika and Volvat, and the AI investments, and those will naturally continue, uh, throughout the year.
Yeah. Just to mention, uh, there's been a lot of questions today. Um, and I have to go for an interview with Dagens Industri here. Um, but, um, Svein Martin, can I see the next couple of questions he can answer? So, um, I'm sorry for being a bit double booked. Uh, usually this won't take this long, and maybe I've given a bit too long answers, but. Uh, so I have to go for that interview. But thank you for listening to me so far. And so Martin will answer the final questions. Just to mention, uh, there's been a lot of questions today.
Yeah. We don't have a lot more questions, but, um, a couple, um, so 750 kroner for the AI solutions. Is that for ambient listening only? And the AI for referrals is a separate product from that which can help expand the 750 going forward. Yes, that's for the base product, the ambient listening. And then, uh, when we add functionality, it has the potential to either increase the revenue base or reach more users depending a bit on how we position it, but there's definitely potential as we add more functionality. Next one, um, can you give an update on the surgery module and whether the market potential of 150 million NOK that you have previously communicated is plausible? Yeah. So Daniel mentioned this in quite detail, but the market is still there. The product is, uh, close to being finalized. So we think that this will be a very important growth driver for Webdoc in the coming years, particularly these types of clinics and also the stock market with these types of clinics. Um, yeah. So the final question we have here is from Viktor Belak. Can you give an update on Germany? And to clarify, selective M&A would primarily occur in Sweden if it happens, I guess. So the update on Germany, Daniel mentioned, uh, on the M&A side, inside. Um. Yeah, I would say the selective M&A that we're looking at now involves only a few companies. It's a handful. And all of it would basically be to strengthen our position in Sweden, as we see now, given that we believe we have enough to work on in Germany at the moment with Data-AL and Webdoc and making them commercially viable. So we don't really have the capacity there to do more M&A at the moment. I mean, in a couple of years' time, there might be an opportunity if we are able to succeed. But then, at the moment, we exclusively focus on the local market, basically. Uh, so with that, that was all the questions we had. So thanks a lot to all for dialing in. And please reach out if you have additional questions. Um, to us.



















